U.S. Approves Moderna's mRNA Flu Vaccine for Adults
U.S. Approves Moderna's mRNA Flu Vaccine for Adults
Updated at: August 10, 2026 at 02:45 AM
FDA made medical history by approving mFlusiva, Moderna’s first mRNA-based influenza vaccine for adults aged 50 and older.
This achievement is significant because, unlike traditional flu shots that are grown in chicken eggs, mRNA technology allows for much faster manufacturing.
This speed is crucial for updating vaccines if flu strains mutate unexpectedly.
The approval process faced early challenges, including initial pushback from the FDA over testing methodology.
However, after an independent advisory committee unanimously recommended the vaccine, the path was cleared for its release.
For adults aged 50 to 64, the approval is full, supported by trials involving 40,000 participants.
Despite the scientific milestone, the vaccine enters a complex landscape.
With vaccine skepticism rising and political figures like Secretary Robert F.
Kennedy Jr. questioning mRNA technology, the success of mFlusiva will depend on both clinical effectiveness and public trust.
Moderna plans to distribute the vaccine in time for the 2026–2027 season, offering a vital new protective tool for vulnerable older populations who face high risks from seasonal flu.
